Clinical and financing moves put Sangamo Therapeutics (SGMO) in focus

Sangamo Therapeutics (SGMO) moved into the spotlight after releasing detailed Phase 1/2 STAAR study data for its Fabry gene therapy candidate, alongside a US$25 million follow on equity offering and a change in its finance leadership.

Against this backdrop of clinical data, financing and leadership change, Sangamo Therapeutics’ share price has been under pressure, with a 30 day share price return of an 18.14% decline and a 1 year total shareholder return of a 71.41% loss, pointing to fading momentum despite recent news interest.

If the ST-920 update has you looking across the sector, this could be a good moment to scan other healthcare stocks that might fit your approach.

With shares trading at US$0.36 after a steep multi year slide, fresh Fabry data, an Accelerated Approval pathway and a US$25 million equity raise all come together here. The key question is whether this punished biotech represents misunderstood value or whether the market is already correctly discounting its future growth.

Most Popular Narrative: 88.9% Undervalued

With Sangamo Therapeutics last closing at $0.36 against a most-followed fair value estimate of $3.25, the current share price sits far below that narrative benchmark.

The successful Phase 1/2 STAAR study in Fabry disease, demonstrating clinically meaningful improvement over existing standards and positive durability, positions Sangamo for potential accelerated FDA approval in 2026, expanding its addressable patient pool and setting the stage for substantial near-term revenue inflection and margin improvement upon launch.

Curious what has to happen for that gap to close? The narrative leans on sharp revenue expansion, a swing to profitability, and a premium earnings multiple. The exact mix may surprise you.

Result: Fair Value of $3.25 (UNDERVALUED)

However, this depends on fresh capital or a Fabry partner arriving before the current cash runway ends, and on clinical or regulatory timelines not slipping further.

Build Your Own Sangamo Therapeutics Narrative

If you see the story differently or simply prefer to stress test the numbers yourself, you can create your own full narrative in just a few minutes, starting with Do it your way.

A great starting point for your Sangamo Therapeutics research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.

Ready for more investment ideas?

If Sangamo has sparked your interest, do not stop here. Use the Simply Wall St Screener now so you do not miss other opportunities lining up.

• Spot emerging names early by checking out these 3534 penny stocks with strong financials that pair lower share prices with stronger underlying financials.
• Consider the AI theme by reviewing these 30 AI penny stocks that are already tied to real products and revenue streams.
• Explore potential price gaps with these 865 undervalued stocks based on cash flows, where current market prices sit below cash flow based estimates.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.